Cargando…
Seroprevalence of SARS-CoV-2 antibodies in South Korea
In 2020, Korea Disease Control and Prevention Agency reported three rounds of surveys on seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in South Korea. SARS-CoV-2 is the virus which inflicts the coronavirus disease 2019 (COVID-19). We analyze the seropreval...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142885/ https://www.ncbi.nlm.nih.gov/pubmed/34054312 http://dx.doi.org/10.1007/s42952-021-00131-7 |
_version_ | 1783696640800980992 |
---|---|
author | Lee, Kwangmin Jo, Seongil Lee, Jaeyong |
author_facet | Lee, Kwangmin Jo, Seongil Lee, Jaeyong |
author_sort | Lee, Kwangmin |
collection | PubMed |
description | In 2020, Korea Disease Control and Prevention Agency reported three rounds of surveys on seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in South Korea. SARS-CoV-2 is the virus which inflicts the coronavirus disease 2019 (COVID-19). We analyze the seroprevalence surveys using a Bayesian method with an informative prior distribution on the seroprevalence parameter, and the sensitivity and specificity of the diagnostic test. We construct the informative prior of the sensitivity and specificity of the diagnostic test using the posterior distribution obtained from the clinical evaluation data. The constraint of the seroprevalence parameter induced from the known confirmed coronavirus 2019 cases can be imposed naturally in the proposed Bayesian model. We also prove that the confidence interval of the seroprevalence parameter based on the Rao’s test can be the empty set, while the Bayesian method renders interval estimators with coverage probability close to the nominal level. As of the 30th of October 2020, the [Formula: see text] credible interval of the estimated SARS-CoV-2 positive population does not exceed 318, 685, approximately [Formula: see text] of the Korean population. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s42952-021-00131-7. |
format | Online Article Text |
id | pubmed-8142885 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Singapore |
record_format | MEDLINE/PubMed |
spelling | pubmed-81428852021-05-25 Seroprevalence of SARS-CoV-2 antibodies in South Korea Lee, Kwangmin Jo, Seongil Lee, Jaeyong J Korean Stat Soc Research Article In 2020, Korea Disease Control and Prevention Agency reported three rounds of surveys on seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in South Korea. SARS-CoV-2 is the virus which inflicts the coronavirus disease 2019 (COVID-19). We analyze the seroprevalence surveys using a Bayesian method with an informative prior distribution on the seroprevalence parameter, and the sensitivity and specificity of the diagnostic test. We construct the informative prior of the sensitivity and specificity of the diagnostic test using the posterior distribution obtained from the clinical evaluation data. The constraint of the seroprevalence parameter induced from the known confirmed coronavirus 2019 cases can be imposed naturally in the proposed Bayesian model. We also prove that the confidence interval of the seroprevalence parameter based on the Rao’s test can be the empty set, while the Bayesian method renders interval estimators with coverage probability close to the nominal level. As of the 30th of October 2020, the [Formula: see text] credible interval of the estimated SARS-CoV-2 positive population does not exceed 318, 685, approximately [Formula: see text] of the Korean population. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s42952-021-00131-7. Springer Singapore 2021-05-24 2021 /pmc/articles/PMC8142885/ /pubmed/34054312 http://dx.doi.org/10.1007/s42952-021-00131-7 Text en © Korean Statistical Society 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Research Article Lee, Kwangmin Jo, Seongil Lee, Jaeyong Seroprevalence of SARS-CoV-2 antibodies in South Korea |
title | Seroprevalence of SARS-CoV-2 antibodies in South Korea |
title_full | Seroprevalence of SARS-CoV-2 antibodies in South Korea |
title_fullStr | Seroprevalence of SARS-CoV-2 antibodies in South Korea |
title_full_unstemmed | Seroprevalence of SARS-CoV-2 antibodies in South Korea |
title_short | Seroprevalence of SARS-CoV-2 antibodies in South Korea |
title_sort | seroprevalence of sars-cov-2 antibodies in south korea |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142885/ https://www.ncbi.nlm.nih.gov/pubmed/34054312 http://dx.doi.org/10.1007/s42952-021-00131-7 |
work_keys_str_mv | AT leekwangmin seroprevalenceofsarscov2antibodiesinsouthkorea AT joseongil seroprevalenceofsarscov2antibodiesinsouthkorea AT leejaeyong seroprevalenceofsarscov2antibodiesinsouthkorea |